- ACADIA Pharmaceuticals reported robust Q2 2026 financial results, significantly beating both EPS and revenue estimates.
- Citigroup reiterated a "Buy" rating and raised its price target for ACADIA Pharmaceuticals, signaling strong analyst confidence.
- Driven by increasing drug sales, ACADIA Pharmaceuticals increased its 2026 revenue forecast, highlighting positive future growth prospects.
ACADIA Pharmaceuticals (NASDAQ: ACAD) is a leading biopharmaceutical stock operating in the biomedical and genetics industry with a market value of approximately $5 billion. This innovative drug development company focuses on developing and selling new medicines. Its stock recently traded at $29.21 per share, showing a daily increase of 2.67% and reaching a 52-week high of $29.48, reflecting positive stock market performance.
On August 10, 2026, the analyst firm Citigroup restated its "Buy" rating for Acadia. A "Buy" rating suggests that an analyst believes the stock will perform well in the future. Citigroup also raised its analyst price target, an estimate of the stock's future price, to $39.00 from its previous target of $35.00, indicating strong investment analysis.
This positive outlook is supported by the company's strong financial performance. In its second quarter of 2026, Acadia reported earnings of $0.18 per share. This figure significantly beat the Zacks Consensus Estimate of $0.06 per share, resulting in a 200% earnings surprise, as highlighted by Zacks Investment Research in its quarterly earnings report.
The company's revenues also surpassed expectations. Acadia generated $307.96 million for the quarter, which was 4.81% above analyst predictions. This marks a notable increase from the $264.57 million in revenue reported in the same quarter of the previous year, indicating robust revenue growth.
This performance was driven by rising sales of its key drugs. Sales for Daybue saw a 30% increase, while Nuplazid sales grew by 9%. Following these results, Acadia increased its own 2026 revenue forecast to a range of $1.24 billion to $1.30 billion, as detailed by Zacks Investment Research, reflecting a positive pharmaceutical industry outlook.